Siltuximab in Large Granular Lymphocytic Leukemia (LGLL)
Status:
Recruiting
Trial end date:
2025-09-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate the safety and effectiveness of siltuximab for
participants being treated for large granular lymphocytic leukemia (LGLL).
Phase:
Early Phase 1
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute